CVC Capital Partners is exploring a multibillion-euro exit from Cooper Consumer Health. The drugmaker Stada, owned by CapVest, has emerged as a potential buyer for the business. Cooper operates several personal care and wellbeing brands, including Baccide and Dermafresh, though early-stage talks provide no guarantee that a deal will actually materialize.

CapVest took control of Stada from Bain Capital and Cinven last year in a deal valuing the German group at $11.3bn including debt. CEO Peter Goldschmidt previously signaled that the company has the financial firepower for meaningful acquisitions. Buying Cooper would allow Stada to bolt on a large consumer health platform barely a year into its new ownership.

Pressure is mounting for private equity firms to return cash to limited partners. European sponsor-backed sales have already reached $70bn this year, a jump of more than 25%. A sale allows CVC to crystallize value while markets remain receptive, especially if other private equity bidders create competitive tension to drive up the final price.

This transaction represents a consolidation play in the European health sector. Stada intends to use its current scale to aggressively expand its geographic reach and product portfolio. CVC seeks to liquidate a high-value asset during a period of increased exit activity across the region.